The main achievements reported in the study included:
- The identification of PHA as first output to be produced by the system. Oakbio compared the economics and technology readiness level of C2B in regards to PHA bioplastic, n-butanol and animal feed. The definition of the overall business cases for the three applications showed a higher technology and market readiness and significantly stronger growth potential in Europe for PHA. Oakbio has therefore decided to focus the development of C2B on the PHA production, calibrating the SME Instrument Phase 2 application accordingly.
- An analysis of the latest regulatory trends in Europe for GHG reduction and carbon capture technologies. This also included the analysis of the EU regulatory framework affecting the manufacture of large bioreactors, in particular the ATEX Directive, which covers equipment and protective systems intended for use in potentially explosive atmospheres.
- An IP landscape analysis to ensure Oakbio’s freedom to operate in Europe. Also, the assessment of the main risks (technical and business) that C2B’s implementation will be likely to face in the two-years-project.
- The definition of a workplan for the development of the C2B pilot plant and for its demonstration with the industrial partner. In this regard, Oakbio has had conversations with CMOs, industrial plants, biotech hubs and research facilities such as BIO Base Europe Pilot Plant and Wroclaw Technology Park, which was eventually selected as base for the Phase 2 project. Oakbio Ltd is a UK based company with offices in London. We deemed it crucial to move our future operations to areas with easier and more affordable access to incentives, high-level labs and scaling-up capacities is easier and less costly. We have therefore drafted a list of hubs and incubators geared toward biotech startups, and assessed the best location for operations according to the following 3 criteria: ease of scaling-up, access to high-level labs and talent, a strong business environment. The Wroclaw Technology Park met all selection criteria. Wrocław Technology Park is currently a place of operation for over 200 companies from the highly-specialized technology sector and a workplace for over 1600 employees of these companies. A group of 12 laboratories and prototyping facilities with world-class equipment, the Technological Line which is unique on the scale of the country, a modern office area, investment plots and the Nowa Siódemka production and storage hall – all this will be at the disposal of Oakbio for the duration of the Innovation Project.